Skip to content

Vaxcyte, Inc. PCVX Lease Liability Payments - Due Year Three

Lease Liability Payments - Due Year Three at other companies

Moderna logo
ModernaMRNA
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s lease liability payments - due year three.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s lease liability payments - due year three?
Vaxcyte, Inc. (PCVX) reported lease liability payments - due year three of $17.86M in Q1 2026.
How has Vaxcyte, Inc.'s lease liability payments - due year three changed year-over-year?
Vaxcyte, Inc.'s lease liability payments - due year three increased by 51.0% year-over-year, from $11.82M to $17.86M.
What does lease liability payments - due year three mean?
The contractual cash obligations for operating and finance leases due in the third year following the balance sheet date. This metric helps in mapping out the long-term fixed cost profile of the company. It is essential for evaluating the sustainability of lease-related cash outflows over a multi-year horizon.